🚀 VC round data is live in beta, check it out!
ALX Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for ALX Oncology and similar public comparables like Heartseed, Transgene, AC Immune, Fennec Pharmaceuticals and more.
ALX Oncology Overview
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Founded
2020
HQ
Employees
80
Website
Sectors
Financials (LTM)
EV
$226M
ALX Oncology Financials
ALX Oncology reported last 12-month revenue of — and negative EBITDA of ($100M).
In the same LTM period, ALX Oncology generated ($100M) in EBITDA losses and had net loss of ($99M).
Revenue (LTM)
ALX Oncology P&L
In the most recent fiscal year, ALX Oncology reported revenue of — and EBITDA of ($99M).
ALX Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($100M) | XXX | ($99M) | XXX | XXX | XXX |
| Net Profit | ($99M) | XXX | ($102M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ALX Oncology Stock Performance
ALX Oncology has current market cap of $277M, and enterprise value of $226M.
Market Cap Evolution
ALX Oncology's stock price is $2.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $226M | $277M | 0.0% | XXX | XXX | XXX | $-0.78 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialALX Oncology Valuation Multiples
ALX Oncology trades at (2.3x) EV/EBITDA.
EV / Revenue (LTM)
ALX Oncology Financial Valuation Multiples
As of March 18, 2026, ALX Oncology has market cap of $277M and EV of $226M.
Equity research analysts estimate ALX Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ALX Oncology has a P/E ratio of (2.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $277M | XXX | $277M | XXX | XXX | XXX |
| EV (current) | $226M | XXX | $226M | XXX | XXX | XXX |
| EV/EBITDA | (2.3x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | (2.2x) | XXX | (2.2x) | XXX | XXX | XXX |
| P/E | (2.8x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ALX Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ALX Oncology Margins & Growth Rates
ALX Oncology's revenue in the last fiscal year grew by —.
ALX Oncology's revenue per employee in the last FY averaged $0.0M.
ALX Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 3% | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ALX Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Heartseed | XXX | XXX | XXX | XXX | XXX | XXX |
| Transgene | XXX | XXX | XXX | XXX | XXX | XXX |
| AC Immune | XXX | XXX | XXX | XXX | XXX | XXX |
| Fennec Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Journey Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ALX Oncology M&A Activity
ALX Oncology acquired XXX companies to date.
Last acquisition by ALX Oncology was on XXXXXXXX, XXXXX. ALX Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ALX Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialALX Oncology Investment Activity
ALX Oncology invested in XXX companies to date.
ALX Oncology made its latest investment on XXXXXXXX, XXXXX. ALX Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ALX Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ALX Oncology
| When was ALX Oncology founded? | ALX Oncology was founded in 2020. |
| Where is ALX Oncology headquartered? | ALX Oncology is headquartered in United States. |
| How many employees does ALX Oncology have? | As of today, ALX Oncology has over 80 employees. |
| Who is the CEO of ALX Oncology? | ALX Oncology's CEO is Jason Lettmann. |
| Is ALX Oncology publicly listed? | Yes, ALX Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of ALX Oncology? | ALX Oncology trades under ALXO ticker. |
| When did ALX Oncology go public? | ALX Oncology went public in 2020. |
| Who are competitors of ALX Oncology? | ALX Oncology main competitors are Heartseed, Transgene, AC Immune, Fennec Pharmaceuticals. |
| What is the current market cap of ALX Oncology? | ALX Oncology's current market cap is $277M. |
| Is ALX Oncology profitable? | No, ALX Oncology is not profitable. |
| What is the current EBITDA of ALX Oncology? | ALX Oncology has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of ALX Oncology? | Current EBITDA multiple of ALX Oncology is (2.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.